GlassScriptPhysician profile
Ellison Croft
NPI 1114462488
$3,281.63
in general payments reported to CMS, 2019-2025
43 companies · $720 in 2025
The $720 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $892 · 2022: $443 · 2023: $844 · 2024: $382 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.30 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.68 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $287.48 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $285.56 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $192.87 | 2021-2025 | Otezla, Repatha |
| Novo Nordisk INC | $177.78 | 2021-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $124.91 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $104.89 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Inspire Medical Systems, INC. | $102.48 | 2024-2025 | Inspire |
| Lilly USA, LLC | $96.36 | 2021-2023 | Mounjaro |
| Pfizer INC. | $92.71 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $78.23 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.77 | 2025 | Xifaxan |
| Indivior INC. | $69.26 | 2025 | Sublocade |
| Corium, LLC | $64.81 | 2022-2023 | Adlarity |
| Eisai INC. | $63.44 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellison Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.